Is Viking Therapeutics a Top Takeover Target?

Its pb obesity candidate, VK2735, is presently being developed successful some injectable and oral formulations. The company's Phase 3 VANQUISH obesity studies are already afloat enrolled, portion absorption expects to initiate Phase 3 trials for the oral tablet aboriginal this year.

The information for Viking's cause pipeline is beardown

In Viking's caller Phase 2 oral obesity study, patients achieved an mean value nonaccomplishment of up to 12.2% aft 13 weeks, with nary plateau observed during the trial. Earlier Phase 2 information involving the injectable mentation demonstrated up to 14.7% value nonaccomplishment aft 13 weeks.

These results substance due to the fact that the obesity marketplace is becoming 1 of the largest pharmaceutical opportunities successful decades.

Analysts wide expect GLP-1 and dual agonist obesity therapies to yet make good implicit $100 cardinal annually. Eli Lilly and Novo Nordisk are already generating tens of billions successful gross from obesity and diabetes drugs similar Zepbound and Wegovy.

Here's the hitch

For ample pharma companies, determination aren't galore late-stage obesity assets near to buy.

That is wherever Viking becomes interesting. Unlike galore smaller obesity cause developers, Viking inactive controls some injectable and oral versions of the aforesaid progressive molecule. Management besides continues emphasizing imaginable attraction dosing opportunities and further metabolic indications beyond obesity itself.

And financially, the institution is comparatively steadfast for biotech stocks astatine this stage. Viking ended Q1 2026 with astir $603 cardinal successful currency and investments, which absorption believes should money operations into 2028. That reduces contiguous financing unit and gives the institution flexibility during concern oregon acquisition negotiations.

Of course, Viking inactive has nary approved products and fundamentally nary meaningful revenue. Investors are valuing the institution astir wholly connected the aboriginal commercialized imaginable of VK2735. Still, astatine caller prices adjacent astir $30 per share, Viking's marketplace capitalization remains dramatically beneath the valuations presently attached to ample obesity franchises.